<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/2fbff65d058c44b4.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-0f82d34644412e97.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/app/layout-24f8abeacb8025a3.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>MSB share price, analysis &amp; company profile - Mesoblast Limited | ASX Desk</title><meta name="description" content="Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/MSB/"/><meta property="og:title" content="MSB share price, analysis &amp; company profile - Mesoblast Limited"/><meta property="og:description" content="Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/MSB/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="MSB share price, analysis &amp; company profile - Mesoblast Limited"/><meta name="twitter:description" content="Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="grid-glow min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/materials/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/compare/BHP-vs-RIO/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search tickerâ€¦" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does MSB do?","acceptedAnswer":{"@type":"Answer","text":"Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain."}},{"@type":"Question","name":"Is MSB a good investment?","acceptedAnswer":{"@type":"Answer","text":"As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility."}},{"@type":"Question","name":"What drives MSB's share price?","acceptedAnswer":{"@type":"Answer","text":"MSB's share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Mesoblast Limited<!-- --> (<!-- -->MSB<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Mesoblast Limited (ASX: MSB) is an Australian-based biotechnology company focused on developing allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory diseases. Their lead product candidate, remestemcel-L (Ryoncil), is in development for acute graft versus host disease (aGVHD) and has been submitted for FDA approval. The company also has other pipeline candidates, including rexlemestrocel-L, targeting chronic heart failure and chronic lower back pain, operating globally from its Australian base.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$3.2B</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold mb-4">Price Chart</h2><div id="tradingview-widget-MSB" style="height:700px;width:100%"><div class="flex h-full items-center justify-center"><div class="flex items-center gap-3 text-sm text-slate-400"><svg class="h-5 w-5 animate-spin text-blue-400" viewBox="0 0 24 24" fill="none"><circle cx="12" cy="12" r="10" stroke="currentColor" stroke-width="3" class="opacity-25"></circle><path d="M4 12a8 8 0 018-8" stroke="currentColor" stroke-width="3" stroke-linecap="round" class="opacity-75"></path></svg>Loading chartâ€¦</div></div></div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>Mesoblast is a clinical-stage biotechnology company with a significant market capitalization of A$3.2 billion, reflecting its advanced pipeline and potential market opportunities. Its current position is heavily reliant on the successful navigation of regulatory pathways, particularly for remestemcel-L (Ryoncil) in the US market, which has faced previous delays. As a biotech, the company&#x27;s financials are characterised by substantial research and development expenses and often net losses, with revenue primarily derived from partnerships or early product sales post-approval.</p><p>The growth outlook for Mesoblast is intrinsically linked to key catalysts such as FDA approval for Ryoncil, positive Phase 3 clinical trial results for its other pipeline candidates, and subsequent commercialisation efforts or strategic partnerships. The company&#x27;s strategic direction involves securing regulatory approvals, particularly in major markets, and leveraging its proprietary cell therapy platform to address significant unmet medical needs in conditions like aGVHD, heart failure, and chronic back pain. Given its speculative nature, success in these areas would be transformative.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->FDA grants full approval for remestemcel-L (Ryoncil) for acute graft versus host disease, leading to significant market penetration and revenue generation.</li><li>â€¢ <!-- -->Positive Phase 3 clinical trial results for rexlemestrocel-L in chronic heart failure or chronic lower back pain open pathways for further regulatory submissions and market expansion.</li><li>â€¢ <!-- -->Mesoblast secures a significant global commercialisation partnership for one or more of its advanced therapies, providing substantial upfront payments and ongoing royalties.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>â€¢ <!-- -->Further regulatory setbacks or outright rejection from the FDA for remestemcel-L (Ryoncil) significantly diminishes its commercial prospects.</li><li>â€¢ <!-- -->Ongoing Phase 3 clinical trials for other pipeline candidates yield negative or inconclusive results, leading to further delays or discontinuation of development.</li><li>â€¢ <!-- -->The company faces challenges in securing adequate capital for its extensive R&amp;D programs, or competition from rival therapies impacts its market potential.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Market Sentiment</h3><div class="mt-4 flex items-center gap-3"><span class="inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-emerald-500/10 border-emerald-500/30 text-emerald-400">ðŸŸ¢<!-- --> <!-- -->Bullish</span><span class="text-xs text-slate-500">Score: <!-- -->+<!-- -->1.00</span></div><div class="mt-4"><div class="flex justify-between text-[10px] uppercase tracking-widest text-slate-500"><span>Bearish</span><span>Bullish</span></div><div class="relative mt-1 h-2 rounded-full bg-ink-900/60"><div class="absolute left-1/2 top-0 h-full w-px bg-slate-600"></div><div class="absolute top-0 h-full w-2 rounded-full bg-emerald-500" style="left:calc(100% - 4px)"></div></div></div><div class="mt-4 flex gap-4 text-xs"><span class="text-emerald-400">â–² <!-- -->18<!-- --> bullish</span><span class="text-red-400">â–¼ <!-- -->0<!-- --> bearish</span><span class="text-slate-500">0<!-- --> neutral</span></div><p class="mt-1 text-xs text-slate-500">Based on <!-- -->18<!-- --> social post<!-- -->s</p><div class="mt-4 space-y-2"><p class="text-xs uppercase tracking-widest text-slate-500">Recent mentions</p><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-05</span><span class="text-emerald-400">â–²</span></div><p class="mt-1.5 text-slate-300">Optimistic outlook for biotech stocks</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-05</span><span class="text-emerald-400">â–²</span></div><p class="mt-1.5 text-slate-300">Optimistic outlook for biotech stocks</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs"><div class="flex items-center gap-2"><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400">hotcopper</span><span class="text-slate-500">2026-02-05</span><span class="text-emerald-400">â–²</span></div><p class="mt-1.5 text-slate-300">Optimistic outlook for biotech stocks</p></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Quarterly Activities/Appendix 4C Cash Flow Report</p><span class="inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400" title="Price sensitive">ðŸš¨ Price Sensitive</span></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>28 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Quarterly Report</span></div><p class="mt-2 text-xs text-slate-400">The ASX announcement for company MSB, a Commitments Test Entity (CTE), details its quarterly cash flow activities and financial position in Appendix 4C of the latest Quarterly Reports.</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Real World Experience with Ryoncil Shows 84% Early Survival</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>26 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Ceasing to be a substantial holder</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>26 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Substantial Holder</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Becoming a substantial holder</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>26 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Substantial Holder</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">FDA Confirms Path to Approval for CLBP</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>18 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Progress Report</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does MSB do?</p><p class="text-slate-400">Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is MSB a good investment?</p><p class="text-slate-400">As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives MSB&#x27;s share price?</p><p class="text-slate-400">MSB&#x27;s share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->2.39</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-emerald-400">21.9<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$3.2B</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">16/12/2004</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->181.24</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$88.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.99</p><p class="text-xs font-semibold text-red-400">-13.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$670M</span><span class="text-blue-300">View analysis</span></div></a><a class="glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/2fbff65d058c44b4.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[2885,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-0f82d34644412e97.js\"],\"default\"]\n8:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-0f82d34644412e97.js\"],\"\"]\n9:I[9275,[],\"\"]\nb:I[1343,[],\"\"]\nc:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"Image\"]\nd:I[5864,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"default\"]\nf:I[6130,[],\"\"]\n6:T51b,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does MSB do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain.\"}},{\"@type\":\"Question\",\"name\":\"Is MSB a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility.\"}},{\"@type\":\"Question\",\"name\":\"What drives MSB's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"MSB's share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation.\"}}]}a:[\"ticker\",\"MSB\",\"d\"]\n10:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/2fbff65d058c44b4.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"eOdkiPUDvTtu3gxxCfEql\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/MSB/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"MSB\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"MSB\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"MSB\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Mesoblast Limited\",\" (\",\"MSB\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Mesoblast Limited (ASX: MSB) is an Australian-based biotechnology company focused on developing allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory diseases. Their lead product candidate, remestemcel-L (Ryoncil), is in development for acute graft versus host disease (aGVHD) and has been submitted for FDA approval. The company also has other pipeline candidates, including rexlemestrocel-L, targeting chronic heart failure and chronic lower back pain, operating globally from its Australian base.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$3.2B\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"$L7\",null,{\"ticker\":\"MSB\"}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"Mesoblast is a clinical-stage biotechnology company with a significant market capitalization of A$3.2 billion, reflecting its advanced pipeline and potential market opportunities. Its current position is heavily reliant on the successful navigation of regulatory pathways, particularly for remestemcel-L (Ryoncil) in the US market, which has faced previous delays. As a biotech, the company's financials are characterised by substantial research and development expenses and often net losses, with revenue primarily derived from partnerships or early product sales post-approval.\",{\"children\":\"Mesoblast is a clinical-stage biotechnology company with a significant market capitalization of A$3.2 billion, reflecting its advanced pipeline and potential market opportunities. Its current position is heavily reliant on the successful navigation of regulatory pathways, particularly for remestemcel-L (Ryoncil) in the US market, which has faced previous delays. As a biotech, the company's financials are characterised by substantial research and development expenses and often net losses, with revenue primarily derived from partnerships or early product sales post-approval.\"}],[\"$\",\"p\",\"The growth outlook for Mesoblast is intrinsically linked to key catalysts such as FDA approval for Ryoncil, positive Phase 3 clinical trial results for its other pipeline candidates, and subsequent commercialisation efforts or strategic partnerships. The company's strategic direction involves securing regulatory approvals, particularly in major markets, and leveraging its proprietary cell therapy platform to address significant unmet medical needs in conditions like aGVHD, heart failure, and chronic back pain. Given its speculative nature, success in these areas would be transformative.\",{\"children\":\"The growth outlook for Mesoblast is intrinsically linked to key catalysts such as FDA approval for Ryoncil, positive Phase 3 clinical trial results for its other pipeline candidates, and subsequent commercialisation efforts or strategic partnerships. The company's strategic direction involves securing regulatory approvals, particularly in major markets, and leveraging its proprietary cell therapy platform to address significant unmet medical needs in conditions like aGVHD, heart failure, and chronic back pain. Given its speculative nature, success in these areas would be transformative.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"FDA grants full approval for remestemcel-L (Ryoncil) for acute graft versus host disease, leading to significant market penetration and revenue generation.\",{\"children\":[\"â€¢ \",\"FDA grants full approval for remestemcel-L (Ryoncil) for acute graft versus host disease, leading to significant market penetration and revenue generation.\"]}],[\"$\",\"li\",\"Positive Phase 3 clinical trial results for rexlemestrocel-L in chronic heart failure or chronic lower back pain open pathways for further regulatory submissions and market expansion.\",{\"children\":[\"â€¢ \",\"Positive Phase 3 clinical trial results for rexlemestrocel-L in chronic heart failure or chronic lower back pain open pathways for further regulatory submissions and market expansion.\"]}],[\"$\",\"li\",\"Mesoblast secures a significant global commercialisation partnership for one or more of its advanced therapies, providing substantial upfront payments and ongoing royalties.\",{\"children\":[\"â€¢ \",\"Mesoblast secures a significant global commercialisation partnership for one or more of its advanced therapies, providing substantial upfront payments and ongoing royalties.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Further regulatory setbacks or outright rejection from the FDA for remestemcel-L (Ryoncil) significantly diminishes its commercial prospects.\",{\"children\":[\"â€¢ \",\"Further regulatory setbacks or outright rejection from the FDA for remestemcel-L (Ryoncil) significantly diminishes its commercial prospects.\"]}],[\"$\",\"li\",\"Ongoing Phase 3 clinical trials for other pipeline candidates yield negative or inconclusive results, leading to further delays or discontinuation of development.\",{\"children\":[\"â€¢ \",\"Ongoing Phase 3 clinical trials for other pipeline candidates yield negative or inconclusive results, leading to further delays or discontinuation of development.\"]}],[\"$\",\"li\",\"The company faces challenges in securing adequate capital for its extensive R\u0026D programs, or competition from rival therapies impacts its market potential.\",{\"children\":[\"â€¢ \",\"The company faces challenges in securing adequate capital for its extensive R\u0026D programs, or competition from rival therapies impacts its market potential.\"]}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Market Sentiment\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center gap-3\",\"children\":[[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-emerald-500/10 border-emerald-500/30 text-emerald-400\",\"children\":[\"ðŸŸ¢\",\" \",\"Bullish\"]}],[\"$\",\"span\",null,{\"className\":\"text-xs text-slate-500\",\"children\":[\"Score: \",\"+\",\"1.00\"]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between text-[10px] uppercase tracking-widest text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"Bearish\"}],[\"$\",\"span\",null,{\"children\":\"Bullish\"}]]}],[\"$\",\"div\",null,{\"className\":\"relative mt-1 h-2 rounded-full bg-ink-900/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"absolute left-1/2 top-0 h-full w-px bg-slate-600\"}],[\"$\",\"div\",null,{\"className\":\"absolute top-0 h-full w-2 rounded-full bg-emerald-500\",\"style\":{\"left\":\"calc(100% - 4px)\"}}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-4 text-xs\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":[\"â–² \",18,\" bullish\"]}],[\"$\",\"span\",null,{\"className\":\"text-red-400\",\"children\":[\"â–¼ \",0,\" bearish\"]}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":[0,\" neutral\"]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1 text-xs text-slate-500\",\"children\":[\"Based on \",18,\" social post\",\"s\"]}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-widest text-slate-500\",\"children\":\"Recent mentions\"}],[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-05\"}],[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":\"â–²\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Optimistic outlook for biotech stocks\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-05\"}],[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":\"â–²\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Optimistic outlook for biotech stocks\"}]]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-2\",\"children\":[[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400\",\"children\":\"hotcopper\"}],[\"$\",\"span\",null,{\"className\":\"text-slate-500\",\"children\":\"2026-02-05\"}],[\"$\",\"span\",null,{\"className\":\"text-emerald-400\",\"children\":\"â–²\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-1.5 text-slate-300\",\"children\":\"Optimistic outlook for biotech stocks\"}]]}]]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Quarterly Activities/Appendix 4C Cash Flow Report\"}],[\"$\",\"span\",null,{\"className\":\"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400\",\"title\":\"Price sensitive\",\"children\":\"ðŸš¨ Price Sensitive\"}]]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"28 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Quarterly Report\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-xs text-slate-400\",\"children\":\"The ASX announcement for company MSB, a Commitments Test Entity (CTE), details its quarterly cash flow activities and financial position in Appendix 4C of the latest Quarterly Reports.\"}]]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Real World Experience with Ryoncil Shows 84% Early Survival\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"26 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],\"\"]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Ceasing to be a substantial holder\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"26 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Substantial Holder\"}]]}],\"\"]}],[\"$\",\"div\",\"3\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Becoming a substantial holder\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"26 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Substantial Holder\"}]]}],\"\"]}],[\"$\",\"div\",\"4\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"FDA Confirms Path to Approval for CLBP\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"18 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Progress Report\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does MSB do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does MSB do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Mesoblast develops allogeneic mesenchymal stromal cell (MSC) therapies for serious inflammatory conditions. Their lead product, remestemcel-L (Ryoncil), targets acute graft versus host disease, while other candidates are for chronic heart failure and chronic lower back pain.\"}]]}],[\"$\",\"div\",\"Is MSB a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is MSB a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"As a clinical-stage biotechnology company, MSB offers substantial upside potential if its therapies gain regulatory approval and achieve commercial success. However, it carries significant risks inherent to drug development, including clinical trial failures and regulatory hurdles, making it a speculative investment with high volatility.\"}]]}],[\"$\",\"div\",\"What drives MSB's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives MSB's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"MSB's share price is primarily driven by announcements regarding clinical trial results, regulatory decisions (especially from the FDA), progress in commercialisation partnerships, and successful capital raisings. News regarding competitor therapies or changes in the broader biotech sector can also influence its valuation.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"2.39\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-emerald-400\",\"children\":[\"21.9\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$3.2B\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"16/12/2004\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/asx/CSL\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"181.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$88.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/PNV\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.99\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-13.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$670M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/1AD\",\"className\":\"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$a\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"grid-glow min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lc\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L8\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L8\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L8\",\"/sectors/materials\",{\"href\":\"/sectors/materials\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L8\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L8\",\"/compare/BHP-vs-RIO\",{\"href\":\"/compare/BHP-vs-RIO\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L8\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Ld\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Ld\",null,{}]}],[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Le\"],\"globalErrorComponent\":\"$f\",\"missingSlots\":\"$W10\"}]]\n"])</script><script>self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"MSB share price, analysis \u0026 company profile - Mesoblast Limited | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/MSB/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"MSB share price, analysis \u0026 company profile - Mesoblast Limited\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/MSB/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"MSB share price, analysis \u0026 company profile - Mesoblast Limited\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest MSB share price overview, what Mesoblast Limited does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>